The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Martin Reck

Department of Thoracic Oncology

Hospital Grosshansdorf

Grosshansdorf

Germany

[email]@web.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany. 2004 - 2012
  • Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, Germany. 2010

References

  1. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Reck, M. Ann. Oncol. (2012) [Pubmed]
  2. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. Reck, M., Thatcher, N., Smit, E.F., Lorigan, P., Szutowicz-Zielinska, E., Liepa, A.M., Winfree, K.B., Peterson, P., Guba, S.C., Socinski, M.A. Lung. Cancer (2012) [Pubmed]
  3. Reviewing the safety of erlotinib in non-small cell lung cancer. Reck, M., Mok, T., Wolf, J., Heigener, D., Wu, Y.L. Expert. Opin. Drug. Saf (2011) [Pubmed]
  4. BIBF 1120 for the treatment of non-small cell lung cancer. Reck, M. Expert. Opin. Investig. Drugs (2010) [Pubmed]
  5. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. Reck, M., van Zandwijk, N., Gridelli, C., Baliko, Z., Rischin, D., Allan, S., Krzakowski, M., Heigener, D. J. Thorac. Oncol (2010) [Pubmed]
  6. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., Manegold, C. Ann. Oncol. (2010) [Pubmed]
  7. Examining the safety profile of angiogenesis inhibitors: implications for clinical practice. Reck, M. Target. Oncol (2010) [Pubmed]
  8. A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. Reck, M. Expert. Rev. Anticancer. Ther (2010) [Pubmed]
  9. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany. Reck, M., Stahel, R.A., von Pawel, J., Karthaus, M., Korfee, S., Serke, M., Schuette, W.H., Eschbach, C., Fink, T.H., Leschinger, M.I., Manegold, C. Respir. Med (2010) [Pubmed]
  10. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Reck, M., Frickhofen, N., Cedres, S., Gatzemeier, U., Heigener, D., Fuhr, H.G., Thall, A., Lanzalone, S., Stephenson, P., Ruiz-Garcia, A., Chao, R., Felip, E. Lung. Cancer (2010) [Pubmed]
  11. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition. Reck, M., Gutzmer, R. Onkologie (2010) [Pubmed]
  12. Gefitinib in the treatment of advanced non-small-cell lung cancer. Reck, M. Expert. Rev. Anticancer. Ther (2009) [Pubmed]
  13. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Reck, M., Crinò, L. Lung. Cancer (2009) [Pubmed]
  14. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., Manegold, C. J. Clin. Oncol. (2009) [Pubmed]
  15. Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case series. Reck, M. Onkologie (2007) [Pubmed]
  16. Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. Reck, M. Future. Oncology. (london,. England) (2006) [Pubmed]
  17. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial. Reck, M., von Pawel, J., Macha, H.N., Kaukel, E., Deppermann, K.M., Bonnet, R., Ulm, K., Hessler, S., Gatzemeier, U. Lung. Cancer (2006) [Pubmed]
  18. Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer. Reck, M., Buchholz, E., Romer, K.S., Krutzfeldt, K., Gatzemeier, U., Manegold, C. Clin. Lung. Cancer (2006) [Pubmed]
  19. Pemetrexed-cisplatin combination in mesothelioma. Reck, M., Gatzemeier, U. Expert. Rev. Anticancer. Ther (2005) [Pubmed]
  20. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Reck, M., Groth, G., Buchholz, E., Goetz, E., Gatzemeier, U., Manegold, C. Lung. Cancer (2005) [Pubmed]
  21. Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC). Reck, M. Anticancer Res. (2005) [Pubmed]
  22. EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients. Reck, M., Gatzemeier, U. Onkologie (2005) [Pubmed]
  23. Chemotherapy in stage-IV NSCLC. Reck, M., Gatzemeier, U. Lung. Cancer (2004) [Pubmed]
 
WikiGenes - Universities